Which hedge funds own SYRE? SPYRE THERAPEUTICS INC, Q2 2026 13F holders
62 tracked hedge funds disclosed a position in SYRE (SPYRE THERAPEUTICS INC) in their Q2 2026 13F filings, worth $2.4bn in total. The largest holder by portfolio weight is Venrock Adviser, LLC at 8.0% of its book. 30 opened a new position this quarter: Integral Health Asset Management, LLC, Cormorant Asset Management, LP, Boxer Capital Management, LLC, Diadema Partners LP. 11 exited: Fairmount Funds Management LLC, Caligan Partners LP, RA Capital Management, L.P..
- 62
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 30
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 11
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $386m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $386m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $2.4bn
- Combined value Sum of the holders' reported positions in the security.
- 5.0%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Fairmount Funds Management LLC | 14.6% | $203m |
| Caligan Partners LP | 3.1% | $44.3m |
| RA Capital Management, L.P. | 0.9% | $81.8m |
| Arrowpoint Investment Partners (Singapore) Pte. Ltd. | 0.5% | $310k |
| Scientech Research LLC | 0.3% | $358k |
| Baker Bros. Advisors LP | 0.3% | $50.4m |
| ExodusPoint Capital Management, LP | 0.04% | $4.4m |
| RWC Asset Management LLP | 0.02% | $412k |
| DeepCurrents Investment Group LLC | 0.01% | $239k |
| Carlyle Group Inc. | 0.0% | $485k |
| Capstone Investment Advisors, LLC | 0.0% | $380k |
Ownership over time
Who discovered SYRE first? Beta
The run: Q2 2025 → Q3 2026, +495%
| HighVista Strategies LLC | Q3 2024 | 0.6% | +5.7 pts |
| B Group, Inc. | Q2 2025 | 1.0% | +5.5 pts |
| Braidwell LP | Q2 2024 | 1.3% | +3.0 pts |
| Paradigm Biocapital Advisors LP high conviction | Q3 2024 | 1.2% | +2.3 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.